[Edaily Starin YUN GI BACK Reporter] Global girl group KATSEYE continued its success by placing two songs simultaneously in the Top 40 of the UK Official Singles Chart. KATSEYE (Photo: HYBE·Geffen Records) According to the latest Official Singles Chart Top 100 (April 4–10) released by the Official Charts Company on April 4 (local time), “Animal,” the pre-release track from KATSEYE’s third EP “WILD,” ranked 16th. It climbed one spot from the previous week and remained on the chart for the sixth consecutive week. The title track of “WILD,” “Hootie Frutti,” also made the list at No. 33. The song has remained in the Top 40 for three consecutive weeks, proving its steady popularity. As a result, Cats Eye placed two songs—“Animal” and “Hootie Frutti”—simultaneously in the Top 40 of this week’s Official Singles Chart. In particular, “Animal” continued to climb even in its sixth week on the chart, raising expectations for its long-term success. The album also continues to make its presence felt in the UK. “Wild,” which previously debuted at No. 2 on the Official Albums Chart, climbed two spots from the previous week to No. 22 on the latest chart. This marks its third consecutive week in the Top 30. With two singles and the album all performing well on the charts, Cat’s Eye’s success in the UK appears to be continuing. “GOLDEN” by Huntrix, the fictional girl group from the Netflix animated series “K-Pop Demon Hunters,” also made it onto the Official Singles Chart Top 100. “GOLDEN” climbed two spots from the previous week to No. 50, marking a resurgence. It has remained on the chart for 63 consecutive weeks, continuing its long-term success.
Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
Shinsegae Co.,Ltd Chairman Chung Yong-jin is returning to the forefront of management at E-MART Co., Ltd.(139480). Unlike in 2013, when he stepped down as a registered director and entrusted the busin…
“Batoclimab,” a treatment for autoimmune diseases developed by HANALL BIOPHARMA CO.,LTD(009420), has received new drug approval in China. This comes approximately nine years after the company licensed…